Propel Funeral Partners trades at $5.04 vs $3.83 fair value with 32% overvaluation despite solid fundamentals and demographic tailwinds creating asymmetric downside risk.
View noteHOLD rating with $10.78 fair value vs $11.20 current price. Market leader with 25.8% share, 5.1% dividend yield, facing battery execution risks.
View noteHealthcare IT company trading at $0.24 vs $0.095 fair value. Strong recurring revenue model offset by execution risks and EMR competition. 60% overvalued.
View noteMarket leader oOh!media trades at $1.77 vs fair value $1.27. EBITDA margins 19.7%, market share 30% but facing government capture risks and competitive erosion.
View noteGovernment software leader trading at 41.6x EBITDA vs 18.5x peers. Fair value $8.71 implies -55% downside. Strong moats face Microsoft threat.
View noteStrong Sell rating with fair value $0.26 vs current $0.85. EBITDA margins of 45.7% unsustainable as gold prices normalise from record highs.
View noteNuix trades at $2.48 vs fair value $1.78. Neo platform shows 132% growth but faces 60% AI disruption probability. EBITDA margins 16.8%, churn rising to 7.1%.
View noteDevelopment-stage uranium leader with 3.10% ore grade advantage. Fair value $12.83 CAD vs current price, 82.7% projected EBITDA margins, binary regulatory catalyst November 2025.
View noteAustralia's #1 wealth platform with 89.2% ROIC trades at $37.14 vs $9.67 fair value. Exceptional margins face inevitable compression as competition intensifies.
View noteMonopoly Rett syndrome treatment with 83.4% margins and A$222m cash. Fair value A$10.46 vs current A$16.93 suggests 62% overvaluation despite exceptional business quality.
View noteNick Scali trades at $19.37 vs fair value $18.34, reflecting 5.6% overvaluation. Strong ANZ market leadership with UK expansion catalyst requiring selective entry timing.
View noteHOLD rating with $3.25 fair value vs $4.49 current price. Strong trophon franchise but CORIS execution risk at 28% premium valuation.
View note